Pharma BD Deal Intelligence
Roche Holding AG / Spark Therapeutics Inc.
2019 · Acquisition/Merger · $4.3B · Complete
Announcement Sentiment
46
Neutral / mixed
Outcome Score
27
Did not work — the deal failed to deliver.
Roche acquired Spark Therapeutics for approximately $4.3 billion ($114.50 per share) in an all-cash tender offer, gaining Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a genetic disease, along with a hemophilia gene therapy pipeline.
Key facts
Announced Feb 25, 2019 Closed Dec 17, 2019 Deal value $4.3B Deal type Acquisition/Merger Therapeutic area Gene Therapy, Hematology, Ophthalmology, Rare Disease Indications RPE65-associated Retinal Dystrophy, Hemophilia A, Hemophilia B Key assets Luxturna (voretigene neparvovec-rzyl), SPK-8011, SPK-9001, Gene therapy manufacturing platform Mechanism AAV-based gene therapy
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
The Pharma Closeout — Deal Intelligence Database.
Announcement Sentiment and Outcome Score from sourced facts.Home ·
Deals ·
Methodology ·
About